Compare Amgen, Inc. (AMGN) vs Verizon Communications Inc (VZ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Verizon Communications Inc — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Verizon Communications Inc trades at $42.35 (market cap $175.87B). The key difference: Amgen, Inc. and Verizon Communications Inc are close in size by market cap, and Verizon Communications Inc pays the higher dividend (6.72%). Which is the better fit depends on your goals.
| AMGN | VZ | |
|---|---|---|
Market Cap | $196.12B | $175.87B |
Sector | Health | Media |
52-Week High | $388.16 | $51.38 |
52-Week Low | $271.18 | $38.40 |
Enterprise Value | $241.41B | $363.38B |
Dividend Yield | 2.77% | 6.72% |
Volume | — | 22,584,735 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Verizon (VZ) trades at $42.12, down 0.28% today, with a bearish technical signal but strong fundamentals including a P/E of 10.27 and consistent earnings beats. Recent news highlights include a new BMW connectivity partnership and inclusion in high-yield dividend stock lists. Cash flow improved significantly in 2025 with net cash flow of $14.9 billion, though long-term debt remains elevated at $121.38 billion.
Outlook: VZ offers value with a 6.7% dividend yield and analyst consensus price target of $48.17 (14% upside). Risks include competitive pressure from SpaceX's Starlink and high debt load. The stock is a buy for income investors seeking stability, but growth may be limited by industry saturation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Verizon Communications Inc
Verizon Communications Inc. is an integrated telecommunications company that provides wire line voice and data services, wireless services, Internet services, and published directory information. The Company also provides network services for the federal government including business phone lines, data services, telecommunications equipment, and payphones.
Read more on VZ →
